Academic literature on the topic 'Immune checkpoint inhibitors (ICIs)'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Immune checkpoint inhibitors (ICIs).'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Immune checkpoint inhibitors (ICIs)"
Farshidpour, Maham, and William Hutson. "Immune Checkpoint Inhibitors Induced Hepatotoxicity; Gastroenterologists’ Perspectives." Middle East Journal of Digestive Diseases 14, no. 2 (April 30, 2022): 244–53. http://dx.doi.org/10.34172/mejdd.2022.279.
Full textShiravand, Yavar, Faezeh Khodadadi, Seyyed Mohammad Amin Kashani, Seyed Reza Hosseini-Fard, Shadi Hosseini, Habib Sadeghirad, Rahul Ladwa, Ken O’Byrne, and Arutha Kulasinghe. "Immune Checkpoint Inhibitors in Cancer Therapy." Current Oncology 29, no. 5 (April 24, 2022): 3044–60. http://dx.doi.org/10.3390/curroncol29050247.
Full textGan, Jiadi, Yihua Huang, Wenfeng Fang, and Li Zhang. "Research progress in immune checkpoint inhibitors for lung cancer in China." Therapeutic Advances in Medical Oncology 13 (January 2021): 175883592110298. http://dx.doi.org/10.1177/17588359211029826.
Full textMakaremi, Shima, Zahra Asadzadeh, Nima Hemmat, Amir Baghbanzadeh, Alessandro Sgambato, Farid Ghorbaninezhad, Hossein Safarpour, et al. "Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects." Biomedicines 9, no. 9 (August 24, 2021): 1075. http://dx.doi.org/10.3390/biomedicines9091075.
Full textMoshirfar, Majid, Noor F. Basharat, Tanner S. Seitz, Briana K. Ply, Yasmyne C. Ronquillo, and Phillip C. Hoopes. "Corneal Transplant Rejections in Patients Receiving Immune Checkpoint Inhibitors." Journal of Clinical Medicine 11, no. 19 (September 25, 2022): 5647. http://dx.doi.org/10.3390/jcm11195647.
Full textKwon, Hyemi, Eun Roh, Chang Ho Ahn, Hee Kyung Kim, Cheol Ryong Ku, Kyong Yeun Jung, Ju Hee Lee, et al. "Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society." Endocrinology and Metabolism 37, no. 6 (December 31, 2022): 839–50. http://dx.doi.org/10.3803/enm.2022.1627.
Full textNardi Agmon, Inbar, Osnat Itzhaki Ben Zadok, and Ran Kornowski. "The Potential Cardiotoxicity of Immune Checkpoint Inhibitors." Journal of Clinical Medicine 11, no. 3 (February 7, 2022): 865. http://dx.doi.org/10.3390/jcm11030865.
Full textHamada, Kazuyuki, Takuya Tsunoda, and Kiyoshi Yoshimura. "Emerging Immune-Monitoring System for Immune Checkpoint Inhibitors." Life 12, no. 8 (August 13, 2022): 1229. http://dx.doi.org/10.3390/life12081229.
Full textSun, Yining, Nan Wang, and Nuo Zhang. "Immune Checkpoint inhibitor Therapy in Various Cancers." Highlights in Science, Engineering and Technology 14 (September 29, 2022): 318–23. http://dx.doi.org/10.54097/hset.v14i.1840.
Full textMazloom, Anita, Nima Ghalehsari, Victor Gazivoda, Neil Nimkar, Sonal Paul, Peter Gregos, Janice Rateshwar, and Uqba Khan. "Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies." Journal of Clinical Medicine 9, no. 8 (August 6, 2020): 2533. http://dx.doi.org/10.3390/jcm9082533.
Full textDissertations / Theses on the topic "Immune checkpoint inhibitors (ICIs)"
Khunger, Monica, Sagar Rakshit, Adrian V. Hernandez, Vinay Pasupuleti, Kate Glass, Matthew D. Galsky, and Petros Grivas. "Premature clinical trial discontinuation in the era of immune checkpoint inhibitors." Wiley-Blackwell, 2018. http://hdl.handle.net/10757/624716.
Full textBackground: Clinical trial completion is critical for new cancer therapies. Premature trial termination or withdrawal is common and impairs progress. We assessed factors of early terminated/withdrawn oncology trials focusing on trials with immune checkpoint inhibitors (ICI), hypothesizing that the latter may be associated with lower rates of premature discontinuation. Materials and Methods: We reviewed all adult, intervention, oncology trials registered in ClinicalTrials.gov (November 16, 2011, to April 16, 2015) to identify all terminated/withdrawn trials and reasons for termination. Logistics regression model was used to identify factors associated with early termination/withdrawal. Discontinuation rate was compared in trials with and without ICI. Results: We identified 12,875 trials (35% industry funded, 12% federal funded), of which 8.5% were prematurely terminated (5%) or withdrawn (3.5%); the main reasons were poor accrual (33%) and logistical (24%). ICI trials (n = 350) had a nonsignificant lower rate of termination or withdrawal compared with all other oncology trials (5.4% vs. 8.5%; p =.9) and were less likely to discontinue due to poor accrual (nonsignificant difference: 21% vs. 33%; p =.4). ICI trials were also less likely to discontinue compared with all other oncology drug trials (e.g., chemotherapy, targeted inhibitors, antiangiogenesis, biologics; 5.4% vs. 7.9%, respectively, nonsignificant difference). The 4-year cumulative incidence of failing to complete for reasons unrelated to toxicity or efficacy was 18% (95% confidence interval 16%–20%). There was no association between annual incidence across different tumor types or accrual goal and rate of trial termination. Conclusion: Poor accrual represents the main cause of early cancer trial termination. Premature termination/withdrawal rate was not significantly lower in ICI compared with other trials. Clinical trial completion remains a high priority and can be influenced by provider and patient factors. Implications for Practice: Clinical trial completion is critical for new cancer therapies. Premature trial termination or withdrawal is common and impairs progress. This study assessed factors of early terminated/withdrawn oncology trials, focusing on trials with immune checkpoint inhibitors (ICI), and found that poor accrual represents the main cause of early cancer trial termination. Premature termination/withdrawal rate was not significantly lower in immune checkpoint inhibitor trials compared to other trials. The discussion herein is focused on measures taken by the National Cancer Institute and other institutions to improve clinical trial accrual and prevent premature clinical trial discontinuation.
Revisión por pares
El-Refai, Sherif M. "EXPLORING THE EFFECT OF CHRONIC INFLAMMATION ON RESPONSE TO IMMUNE CHECKPOINT INHIBITORS IN CANCER." UKnowledge, 2018. https://uknowledge.uky.edu/pharmacy_etds/82.
Full textAbdo, Mustafa [Verfasser]. "Prediction of patients’ response to immune checkpoint inhibitors in the treatment of advanced NSCLC / Mustafa Abdo." Göttingen : Niedersächsische Staats- und Universitätsbibliothek Göttingen, 2021. http://d-nb.info/1228623848/34.
Full textTannous, Désirée. "The combination of Gadolinium-based nanoparticles, radiotherapy and immune checkpoint inhibitors : a novel therapeutic opportunity for cancer treatment." Thesis, université Paris-Saclay, 2022. http://www.theses.fr/2022UPASL082.
Full textScientific discoveries linked to radiotherapy are in continuous progress and almost 60% of cancer diagnosed patients are treated with radiotherapy. However, radiation therapy still faces many limitations due to radioresistance and the side effects inflected on healthy tissues. To overcome these factors, a particular interest has been aroused on the role that nanomedicine could play in the improvement of immune-mediated anti-tumor response. In this context, we decided to assess the ability of the combination of Gadolinium nanoparticles (AGuIX) with ionizing radiation (IR) to stimulate an anti-tumor immunological response and to increase the effectiveness of radiotherapy combined to immune checkpoint blockers.AGuIX are very small nanoparticles composed of a polysiloxane matrix and gadolinium chelates. Thanks to the magnetic properties of gadolinium, these nanoparticles play the role of a contrast agent, in addition to its radiosensitizing properties, thus allowing a better targeting and an enhanced therapeutic index.Our work reveals the ability of the AGuIX+IR combination to induce genomic instability and to stimulate immunomodulatory cell signaling pathways in treated human and murine cancer cells. In parallel, we demonstrate the anti-tumor activity of this combination by assessing tumor growth and overall survival using a preclinical model of immunocompetent mice bearing tumors. Our results strongly demonstrate a synergistic effect of AGuIX + IR combination on tumor growth and overall survival by stimulating the immune system. Finally, we reveal the capacity of AGuIX + IR combination to overcome immune checkpoint blockers resistance.In conclusion, our work shows that the combination of AGuIX+IR stimulates immunomodulatory signaling pathways, induces a strong synergistic anti-tumor response and helps overcoming resistance to immunotherapies
Seeber, Tonia Olivia [Verfasser]. "Primary Resistance to Immune Checkpoint Inhibitors in Patients with Metastatic Melanoma : Prognosis, Subsequent Therapies and Survival / Tonia Olivia Seeber." Tübingen : Universitätsbibliothek Tübingen, 2021. http://d-nb.info/123272582X/34.
Full textSodre, De Castro Laino Andressa. "Targeting Histone Deacetylases in Melanoma and T-cells to Improve Cancer Immunotherapy." Scholar Commons, 2016. http://scholarcommons.usf.edu/etd/6144.
Full textGehring, Svenja [Verfasser], and Ulrich M. [Akademischer Betreuer] Lauer. "A novel treatment strategy for colorectal cancer : Measles vaccine virus-induced oncolysis in combination with immune checkpoint inhibitors and NK cells / peripheral blood mononuclear cells / Svenja Gehring ; Betreuer: Ulrich M. Lauer." Tübingen : Universitätsbibliothek Tübingen, 2020. http://d-nb.info/1204421951/34.
Full textCohen, Romain. "Caractérisation phénotypique et clinique des cancers colorectaux métastatiques avec instabilité des microsatellites Clinical and molecular characterization of hereditary and sporadic metastatic colorectal cancer harbouring microsatellite instability/DNA mismatch repair deficiency Association of primary resistance to immune checkpoint inhibitors in metastatic colorectal cancer with misdiagnosis of microsatellite instability or mismatch repair deficiency status." Thesis, Sorbonne université, 2018. http://www.theses.fr/2018SORUS313.
Full textMicrosatellite instability (MSI) is a tumor phenotype linked to somatic or germline inactivating alterations of DNA mismatch repair (MMR) genes. MSI is observed in approximately 5% of metastatic colorectal cancers (mCRC) and has recently emerged as a major positive predictive biomarker for the efficacy of immune checkpoint inhibitors (ICKi) amongst mCRC patients. The objectives of my work was to clinically and molecularly characterize MSI mCRC, to evaluate the accuracy of MSI screening methods and the response to immunotherapy in the context of ICKi clinical trials. Fist, I show that sporadic and inherited MSI mCRC display distinct natural history (Cohen et al., Eur J Cancer 2017). In a second work, I show that MSI testing in routine practice is associated with almost 10% of false positives due to misinterpration of IHC and PCR assays. Moreover, these false-positives are the main cause of mCRC primary resistance to ICKi observed in clinical trials (Cohen*, Hain* et al., JAMA Oncol. 2018). After summarizing the literature concerning MSI, its consequences on CRC and immunotherapy, I present the results of the nosologic and diagnostic works developed during this doctoral thesis. Then I will go on perspectives in the context of MSI cancer
Moya, Plana Antoine. "Recherche de biomarqueurs pronostiques dans le mélanome muqueux non opérable et/ou métastatique : Régulation traductionnelle de SOX10 par l’hexokinase 2 et modulation de l'agressivité tumorale dans le mélanome cutané Prognostic Value and Therapeutic Implications of Nodal Involvement in Head and Neck Mucosal Melanoma Evaluation of the Efficacy of Immunotherapy for Non-Resectable Mucosal Melanoma Oncologic Outcomes, Prognostic Factor Analysis and Therapeutic Algorithm Evaluation of Head and Neck Mucosal Melanomas in France Mélanomes cutanés cervico-faciaux Prognostic 18F-FDG PET Biomarkers in Metastatic Mucosal and Cutaneous Melanoma Treated with Immune Checkpoint Inhibitors Targeting PD-1 and CTLA-4." Thesis, université Paris-Saclay, 2020. http://www.theses.fr/2020UPASS069.
Full textMucosal melanoma is a rare tumor with a high metastatic potential. Immunotherapy has promising results in this aggressive subtype of melanoma. In a cohort of 23 patients with non-resectable and/or metastatic mucosal melanoma who received anti-PD1 immunotherapy, we showed that the activation of the eukaryotic translation initiation complex, eIF4F, was a strong prognostic biomarker of response. This activation was assessed with a proximity ligation assay between eIF4E and eIF4G. The other biomarkers, such as the PD-L1 tumoral expression or the characteristics of tumor-infiltrating lymphocytes, had no prognostic value in this cohort.Aerobic glycolysis is usually the main metabolic pathway in tumor cells during cancerogenesis. This specificprocess is called “Warburg effect”. During melanomagenesis, we observed a positive correlation between the expression level of hexokinase 2 (HK2, first enzyme of glycolysis) and the tumor invasiveness. In this study, we showed that inhibition of HK2 expression (by siRNA) induced, in vitro, a major decrease of migration and invasion potential independently of the basal glycolytic metabolism or HK2 expression level in the cell lines. Moreover, performing a polysome profiling analysis, we demonstrated that HK2 was regulating the translation of SOX10 mRNA, a transcription factor involved in initiation and progression of melanoma. We, then, realized an RNA immunoprecipitation in formaldehyde and showed that HK2 was an RNA-binding protein, able to interact with the SOX10 mRNA
Rodrigues, Soraia Gonçalves Pereira. "Immune checkpoint inhibitors for the treatment of gastric cancer." Master's thesis, 2021. https://hdl.handle.net/10216/134392.
Full textGastric cancer (GC) is the fifth most incident and the fourth deadliest cancer worldwide. GC is a heterogeneous disease from the histological and molecular standpoints. This malignancy is mostly diagnosed at advanced stages of the disease, where the available therapeutic interventions are not effective. The emergence of immunotherapy has transformed the landscape of cancer treatment, including GC, and currently immune checkpoint inhibitors have been approved for the treatment of patients with recurrent/metastatic GC. This review summarizes the main clinical trials evaluating the use of immune checkpoint inhibitors in GC. It also highlights the potential of biomarkers for patient selection for GC immune checkpoint inhibition therapy, including PD-L1 expression and tumor mutational burden, and characteristics of the GC molecular classification, such as microsatellite instability status and Epstein-Barr virus infection, as predictors of response to blockade of the PD-1/PD-L1 axis.
Books on the topic "Immune checkpoint inhibitors (ICIs)"
Balogh, Erin, and Sharyl J. Nass, eds. Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors. Washington, D.C.: National Academies Press, 2019. http://dx.doi.org/10.17226/25405.
Full textIto, Fumito, and Marc Ernstoff. Immune Checkpoint Inhibitors in Cancer. Elsevier - Health Sciences Division, 2018.
Find full textImmune Checkpoint Inhibitors in Cancer. Elsevier, 2019. http://dx.doi.org/10.1016/c2016-0-05251-8.
Full textVentures, Medtech. Immune Checkpoint Inhibitors: Technology and Market Forecast. Independently Published, 2020.
Find full textImmune Checkpoint Inhibitors - New Insights and Recent Progress [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.100958.
Full textDermime, Said, Maysaloun Merhi, and Taha Merghoub. Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer. Frontier Media SA, 2021. http://dx.doi.org/10.3389/978-2-88971-863-4.
Full textNational Comprehensive Cancer Network® (NCCN®). NCCN Guidelines for Patients® Immunotherapy Side Effects: Immune Checkpoint Inhibitors. National Comprehensive Cancer Network® (NCCN®), 2022.
Find full textBoard on Health Care Services, National Cancer Policy Forum, Sharyl J. Nass, National Academies of Sciences, Engineering, and Medicine, and Health and Medicine Division. Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors: Proceedings of a Workshop. National Academies Press, 2019.
Find full textBoard on Health Care Services, National Cancer Policy Forum, Sharyl J. Nass, National Academies of Sciences, Engineering, and Medicine, and Health and Medicine Division. Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors: Proceedings of a Workshop. National Academies Press, 2019.
Find full textBoard on Health Care Services, National Cancer Policy Forum, Sharyl J. Nass, National Academies of Sciences, Engineering, and Medicine, and Health and Medicine Division. Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors: Proceedings of a Workshop. National Academies Press, 2019.
Find full textBook chapters on the topic "Immune checkpoint inhibitors (ICIs)"
Zarifa, Abdulrazzak, Juan Lopez-Mattei, Nicolas Palaskas, Cezar Iliescu, Jean-Bernard Durand, and Peter Y. Kim. "Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity." In Advances in Experimental Medicine and Biology, 277–85. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-41008-7_15.
Full textArora, Sandeep, Saurabh Gupta, and Nidhi Garg. "Immune Checkpoint Inhibitors." In Metastatic Diseases, 207–24. Boca Raton: Apple Academic Press, 2021. http://dx.doi.org/10.1201/9781003043249-14.
Full textLau, Keith C. K., Benson Weyant, and Carlos Cervera. "Immune Checkpoint Inhibitors." In Infectious Complications in Biologic and Targeted Therapies, 233–51. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-11363-5_13.
Full textPalaskas, Nicolas L., Eric H. Yang, and Tomas G. Neilan. "Immune Checkpoint Inhibitor (ICI)-Associated Myocarditis." In Atlas of Imaging in Cardio-Oncology, 27–37. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-70998-3_3.
Full textZarifa, Abdulrazzak, Juan Lopez-Mattei, Nicolas L. Palaskas, Cezar Iliescu, Jean-Bernard Durand, and Peter Y. Kim. "Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity." In Advances in Experimental Medicine and Biology, 377–87. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-79308-1_15.
Full textGerber, Peter Arne. "Oncology: Immune Checkpoint Inhibitors." In Cutaneous Drug Hypersensitivity, 155–59. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-82743-4_16.
Full textMahdavi Sharif, Pouya, Mahsa Keshavarz-Fathi, and Nima Rezaei. "Biomarkers for Immune Checkpoint Inhibitors." In Cancer Immunology, 449–63. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-50287-4_25.
Full textTian, Yun, Hamzah Abu-Sbeih, and Yinghong Wang. "Immune Checkpoint Inhibitors-Induced Colitis." In Advances in Experimental Medicine and Biology, 151–57. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-030-02505-2_7.
Full textTian, Yun, Hamzah Abu-Sbeih, and Yinghong Wang. "Immune Checkpoint Inhibitors-Induced Hepatitis." In Advances in Experimental Medicine and Biology, 159–64. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-030-02505-2_8.
Full textD’Angelo, Sandra P., and Ciara M. Kelly. "Immune Checkpoint Inhibitors in Sarcoma." In Immunotherapy of Sarcoma, 125–37. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-93530-0_7.
Full textConference papers on the topic "Immune checkpoint inhibitors (ICIs)"
Kesireddy, Meghana, Apar Ganti, Alissa Marr, and Makayla Schissel. "1245 Safety and efficacy of immune checkpoint inhibitors (ICIs) in patients with pre-existing organ dysfunction." In SITC 37th Annual Meeting (SITC 2022) Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/jitc-2022-sitc2022.1245.
Full textAO, Georgina Long, Tracy Tang, Abraham Apfel, David Paulucci, Scott Chasalow, Daniel Tenney, Gina Fusaro, et al. "608 Predicting primary resistance and exploring mechanisms in patients with advanced melanoma treated with immune checkpoint inhibitors (ICIs)." In SITC 37th Annual Meeting (SITC 2022) Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/jitc-2022-sitc2022.0608.
Full textShah, Neil J., Ghassan AL-Shbool, Matthew Blackburn, Michael Cook, William J. Kelly, Anas Belouali, Sebastian Ochoa, et al. "Abstract 3230: Safety and efficacy of immune checkpoint inhibitors (ICIs) in patients with HIV, hepatitis B, or hepatitis C viral infections." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-3230.
Full textWang, Xinan, Biagio Ricciuti, Joao V. Alessi, Tom Nguyen, Mark M. Awad, Xihong Lin, Bruce E. Johnson, and David C. Christiani. "Abstract 370: Smoking history as an independent predictor for immune checkpoint inhibitors (ICIs) in metastatic non-small cell lung cancer (NSCLC)." In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-370.
Full textShah, Neil J., Ghassan AL-Shbool, Matthew Blackburn, Michael Cook, William J. Kelly, Anas Belouali, Sebastian Ochoa, et al. "Abstract 3230: Safety and efficacy of immune checkpoint inhibitors (ICIs) in patients with HIV, hepatitis B, or hepatitis C viral infections." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-3230.
Full textBarreto, Maria Eduarda Slhessarenko Fraife, Arthur Malzyner, Nelson Hamerschlak, Maurício Muradian, Alessandra Delavance, and Lívia Almeida Dutra. "Myasthenia gravis, myositis, myocarditis and anti-titin antibodies after Nivolumab/Ipilimumab: response with plasmapheresis." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.379.
Full textFunakoshi, Tomohiro, Hyman Muss, and Stergios Moschos. "Abstract A159: Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A meta-analysis of randomized controlled trials." In Abstracts: CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16-19, 2015; New York, NY. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/2326-6074.cricimteatiaacr15-a159.
Full textHsieh, Yi-Lin, Pei-Ning Yu, Yi-Hua Jan, Meng-Shao Lai, Woei-Fuh Wang, De-Wei Zhuo, Shu-Jen Chen, Jen-Hao Cheng, Kien Thiam Tan, and Yu-Li Su. "Abstract 3177: Panel-derived tumor mutational burden (TMB) is associated with the response to the immune checkpoint inhibitors (ICIs) in urothelial cancers." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-3177.
Full textCrequit, Perrine, Alexandre Vivot, Raphael Porcher, and Jacques Cadranel. "Benefit of immune checkpoint inhibitors (ICIs) for second-line treatment of advanced non-small cell lung cancer (NSCLC) using restricted mean survival time (RMST)." In ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.pa2807.
Full textSingh, Neeraj, Smita Agrawal, and Babu Narayanan. "531 Identifying genetic factors for resistance and response to immune checkpoint inhibitors (icis) in advanced non-small cell lung cancer (nsclc) patients using real-world data." In SITC 37th Annual Meeting (SITC 2022) Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/jitc-2022-sitc2022.0531.
Full textReports on the topic "Immune checkpoint inhibitors (ICIs)"
Tinker, Anna V., Neesha C. Dhani, Prafull Ghatage, Deanna McLeod, Vanessa Samouëlian, Stephen A. Welch, and Alon D. Altman. Immune Checkpoint Inhibitors in Pretreated Metastatic Endometrial Cancer. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, January 2023. http://dx.doi.org/10.37766/inplasy2023.1.0038.
Full textPeng, Yinglong, Jinwei Chen, Ziyan Wang, Yihui Cao, and Jie Zhao. A Systematic Review and meta-analysis of the efficacy of immunotherapy in the treatment of non-small cell lung cancer. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2022. http://dx.doi.org/10.37766/inplasy2022.6.0094.
Full textCrocetto, Felice, Carlo Buonerba, Luca Bardi, Antonio Verde, Simone Cilio, Biagio Barone, Gabriele Barbato, et al. Cardiovascular adverse events in patients with kidney cancer receiving combination of angiogenesis inhibitors plus immune checkpoint inhibitors vs. angiogenesis inhibitors vs. immune checkpoint inhibitors: a network analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, December 2021. http://dx.doi.org/10.37766/inplasy2021.12.0060.
Full textYang, Kaili. Retreatment with immune checkpoint inhibitors in solid tumors: a systematic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2020. http://dx.doi.org/10.37766/inplasy2020.4.0041.
Full textWang, He, Jun Chen, Xiaoling Wang, and Jun Dang. Neoadjuvant immune checkpoint inhibitor in combination with chemotherapy or chemoradiotherapy in resectable esophageal cancer: A systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2022. http://dx.doi.org/10.37766/inplasy2022.6.0052.
Full textYao, Jiannan, Manyu Li, and Guangyu An. Dermatolagic adverse events from immune-checkpoint inhibitors combination therapy:a systematic review and meta analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2020. http://dx.doi.org/10.37766/inplasy2020.5.0068.
Full textJiang, Juan, Xiongmin Guo, Chengping Hu, and Jiayi Liu. Incidence of active tuberculosis after the use of immune checkpoint inhibitors in cancer patients. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, July 2022. http://dx.doi.org/10.37766/inplasy2022.7.0078.
Full textWang, Yan, and Qunqin Ni. Prognostic and clinicopathological significance of systemic immune-inflammation index in cancer patients receiving immune checkpoint inhibitors: a meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, January 2023. http://dx.doi.org/10.37766/inplasy2023.1.0018.
Full textChen, Baoqing, Chen Yang, Qiaoqiao Li, Mihnea Dragomir, and George A. Calin. Effects of proton pump inhibitors in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2020. http://dx.doi.org/10.37766/inplasy2020.10.0088.
Full textGonzalez, Brian, Sarah Eisel, Kristine Bowles, Aasha Hoogland, Brian James, Brent Small, Susan Sharpe, et al. Protocol: Meta-Analysis of Quality of Life in Cancer Patients Treated with Immune Checkpoint Inhibitors. INPLASY - International Platform of Registered Systematic Review Protocols, April 2020. http://dx.doi.org/10.37766/inplasy2020.4.0203.
Full text